Shanghai Kindly Medical Instruments (1501) Fair Value & Analysis
Healthcare · HK · Market cap HK$6.6B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 3 days ago
Share price −1.7% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from HK$22.76 (bear) to HK$38.33 (bull), base HK$30.54. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 67/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$10.64 – HK$40.36 · fair‑value band HK$22.76 – HK$38.33 · the HK$33.40 price screens above the HK$30.54 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Shanghai Kindly Medical Instruments (1501) currently trades at HK$33.40, while our model-based Fair Value estimate is HK$30.54, implying the stock looks roughly 8.6% fairly valued today. The Quality Score stands at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Shanghai Kindly Medical Instruments generated revenue of HK$1.1B at a net margin of 20.5%. Revenue grew 31.5% year over year. It earns a return on equity of 12.0%. Net debt stands at HK$106M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$22.76 (bear case) to HK$38.33 (bull case); at HK$33.40, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 19% below its 52-week high and 67% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at -9%, 1501 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (HK$45.38) versus Dividend Discount (HK$4.14). Highest evidence: Growth DCF (80).
Notify me when 1501 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 68 · Market factors (momentum, volatility) 60
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai INT Medical Instruments Co., Ltd., together with its subsidiaries, engages in the research and development, manufacture, and sale of cardiovascular interventional medical devices in Mainland China, Europe, the United States, and internationally.
Full company description
Shanghai INT Medical Instruments Co., Ltd., together with its subsidiaries, engages in the research and development, manufacture, and sale of cardiovascular interventional medical devices in Mainland China, Europe, the United States, and internationally. It offers transradial and femoral pressure bandage, hydrophilic guidewire, pressure Y-connector set, PTFE guidewire, PTCA balloon dilatation catheter, noncompliant balloon dilatation catheter, compression femoral artery tourniquet, vascular sheaths for single use, push-to-thread balloon dilation pressure pump, guide extension catheter, angiography catheter, guiding catheter, micro guidewire and catheter, cardiac valves balloon inflation catheter, guidewire, introducer set, braided introducer sheath, inflation device, pressure transducer, manifold kit, stopcocks, sterile seldinger needle, Y-connector pack, extension tube, high pressure manifold, and angiography syringe products. The company also provides medical electric suction pumps, intracranial thrombus aspiration and balloon guiding catheters, sterile suction pipettes, embolic protectors, angiography and distal access catheters, and pressure bandages; biodegradable sinus drug stent and thrombus aspiration systems, perfusion catheters, and biodegradable drug eluting sinus stents; joint intervention and introducer tool kits; and pressure controlled suction and single-use digital flexible ureteroscope products. In addition, it offers infusion connectors and accessories, disposable automatic umbilical cord clamps, burette infusion sets without needle, foley catheters, infusion pumps, vaginal dilators; 3D medical surgical fask masks, and disposal respirator FFP2 NR products; and valves, and metal wire processing and pressure gauges. The company was formerly known as Shanghai Kindly Medical Instruments Co., Ltd. and changed its name to Shanghai INT Medical Instruments Co., Ltd. in January 2024. The company was founded in 2006 and is headquartered in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai Kindly Medical Instruments reported revenue of HK$1.1B in FY2025 versus HK$465M in FY2021, a compound +23.1%/yr. Reported net income was HK$219M in FY2025, compounding +11.2%/yr from FY2021.
Watch 1501: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 202 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $401.27 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €164.40 | €68.55 | -58% |
| Medline Inc MDLN | $35.50 | $30.15 | -15% |
| Becton, Dickinson and Company BDX | $181.41 | $100.46 | -45% |
| Alcon Inc ALC | $73.58 | $39.78 | -46% |
| ResMed Inc RMD | $226.00 | $187.89 | -17% |
| West Pharmaceutical Services, Inc WST | $352.29 | $141.58 | -60% |
| Sartorius Stedim Biotech S.A DIM | €180.30 | €48.88 | -73% |
| Coloplast A/S COLOB | kr 429.70 | kr 382.22 | -11% |
| Gan & Lee Pharmaceuticals., a biopharmaceutical company, 603087 | ¥77.48 | ¥27.22 | -65% |
Compare Shanghai Kindly Medical Instruments with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai Kindly Medical Instruments (1501) overvalued or undervalued?
What is the fair value of 1501?
What is the quality score of 1501?
What is the revenue of Shanghai Kindly Medical Instruments (1501)?
What is the net profit margin of 1501?
Does Shanghai Kindly Medical Instruments pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai Kindly Medical Instruments and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.